WMT - Weight Loss Drugs Wegovy Ozempic Gain Traction With Millennials High Earners: New Survey Results | Benzinga
Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have dominated headlines in 2023 with increased interest and the impact being discussed by food and drink companies.
Here's a look at the consumer segments that might be driving the enthusiasm and demand for these GLP-1 drugs.
What Happened: Pharmaceutical companies that are behind these weight loss drugs have witnessed their shares rise in 2023. As analysts and investors point to potential shifts in consumer behavior, food and beverage companies have seen stress on their stock values, anticipating reduced demand for their offerings.
Morning Consult’s recent survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy.
The survey found that 12% of adults are very interested in the weight loss drugs, with 16% saying they were somewhat interested in the drugs. Fourteen percent said they were not too interested in the weight loss drugs, and 48% said they were not interested at all in the drugs.
The survey indicates heightened interest among respondents who reported being well-informed about the weight loss ...